Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Journal of Hematology & Oncology|October 27, 2015
Complexity of FGFR signalling in metastatic urothelial cancerAlejo Rodriguez-Vida, Matilde Saggese, Simon Hughes, et al.
Neurology|September 2, 2016
Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproateRebecca L Bromley, Rebecca Calderbank, Christopher P Cheyne, et al.
BMJ Open Respiratory Research|February 10, 2025
Radiological abnormalities persist following COVID-19 and correlate with impaired health-related quality of life: a prospective cohort study of hospitalised patientsRobert Sykes, Andrew J Morrow, Kenneth Mangion, et al.
Clinical Interventions in Aging|February 17, 2022
Delivering Cognitive Stimulation Therapy (CST) Virtually: Developing and Field-Testing a New FrameworkLuke Perkins, Emily Fisher, Cerne Felstead, et al.
Cancer Research|June 13, 2015
Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical SamplesMargaret H Veldman-Jones, Roz Brant, Claire Rooney, et al.
Cancer Research|February 29, 2012
AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase familyPaul R Gavine, Lorraine Mooney, Elaine Kilgour, et al.
Nature Communications|May 31, 2018
STEF/TIAM2-mediated Rac1 activity at the nuclear envelope regulates the perinuclear actin capAnna Woroniuk, Andrew Porter, Gavin White, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2017
A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung CancersPaul K Paik, Ronglai Shen, Michael F Berger, et al.
Molecular Cancer Therapeutics|August 24, 2016
Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547Oona Delpuech, Claire Rooney, Lorraine Mooney, et al.
British Journal of Cancer|February 23, 2024
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancerCath Eberlein, Stuart C Williamson, Lorna Hopcroft, et al.
Pageof 4